Home | About the eMC | Help | Mobile

eMC - trusted, up to date and comprehensive information about medicines

Search medicine/company name only

Search full document

Medicine name A-Z | Active ingredient A-Z | Pharmaceutical company A-Z | Latest medicine updates | Yellow card report

Stiefel
Stockley Park West, , Uxbridge, Middlesex, UB11 1BT , UK Telephone: +44 (0)800 221 441 Fax: +44 (0)208 990 4328 Medical Information e-mail: customercontactuk@gsk.com Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 22/03/2011

SPC	Polytar Plus

Table of Contents

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT

Go to top of the page

1. NAME OF THE MEDICINAL PRODUCT

Polytar Plus

Go to top of the page

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Tar Blend 1% w/w

Go to top of the page

3. PHARMACEUTICAL FORM

Medicated shampoo for topical use.

Go to top of the page

4. CLINICAL PARTICULARS

Go to top of the page

4.1 Therapeutic indications

Polytar Plus is indicated as an aid in the treatment of scalp disorders such as psoriasis, seborrhoea, pruritus and dandruff. Polytar Plus is also of value in the removal of ointments and pastes used in the treatment of psoriasis.

Go to top of the page

4.2 Posology and method of administration

The following dosages and schedules are applicable for adults, children and the elderly.

The hair should be wetted and sufficient Polytar Plus applied to produce an abundant lather. The scalp and adjacent areas should be vigorously massaged with the fingertips. The hair should then be thoroughly rinsed and the procedure repeated.

Polytar Plus should be used once or twice weekly.

Go to top of the page

4.3 Contraindications

None stated.

Go to top of the page

4.4 Special warnings and precautions for use

Polytar Plus contains arachis oil (peanut oil) and should not be used by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to soya, patients with soya allergy should also avoid Polytar Plus.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

None stated.

Go to top of the page

4.6 Pregnancy and lactation

There are no restrictions on the use of Polytar Plus during pregnancy or lactation.

Go to top of the page

4.7 Effects on ability to drive and use machines

None stated.

Go to top of the page

4.8 Undesirable effects

None stated.

Go to top of the page

4.9 Overdose

None stated.

Go to top of the page

5. PHARMACOLOGICAL PROPERTIES

Go to top of the page

5.1 Pharmacodynamic properties

While the mode of action of tars are not fully established, their therapeutic effect has been observed over many years. It has been postulated that tars work by exerting a cytostatic action following an initial cytoproliferative effect. This slowing of the keratinisation process in the epidermal layer and reduction in the rate of epidermal turnover promoting a return to normal keratinisation.

Go to top of the page

5.2 Pharmacokinetic properties

Not applicable. The product acts at the site of application.

Go to top of the page

5.3 Preclinical safety data

Not applicable.

Go to top of the page

6. PHARMACEUTICAL PARTICULARS

Go to top of the page

6.1 List of excipients

Coconut diethanolamide, Hexylene glycol, Volpo N10, Oleyl alcohol, Polysorbate 80, Triton X100, Fragrance 5412, Polypeptide SF, Imadozolidinyl Urea, Triethanolamine Lauryl Sulphate, Citric acid, Purified water

Go to top of the page

6.2 Incompatibilities

None stated.

Go to top of the page

6.3 Shelf life

a) For the product as packaged for sale

3 years

b) After first opening the container

Comply with expiry date

Go to top of the page

6.4 Special precautions for storage

None